In keeping with prior randomized trials, Alliance N0574 demonstrated that SRS+WBRT provides superior intracranial disease control but worsens QOL and neurocognitive abilities, without improving survival, compared to SRS alone for patients with good performance status and 1-3 brain metastases, none larger than 3 cm in max diameter. Should SRS+WBRT still be considered for patients with high DS-GPA, as suggested by a post-hoc analysis of JROSG 99-1, or in patients who may not adhere to the close surveillance regimen used in Alliance N0574?